SignPath Pharma, Inc. - FORM 10-K - EX-10.7 - AMENDMENT, DATED AUGUST 23, 2012, TO THE LIPOSOMAL FORMULATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH. - April 9, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SignPath Pharma, Inc.Financial_Report.xls
EX-4.9 - FORM OF CLASS D COMMON STOCK PURCHASE WARRANT - SignPath Pharma, Inc.signpathexh49.htm
EX-10.6 - AMENDMENT DATED APRIL 12, 2012 TO THE LIPSOMAL FOUNDATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORCHUNG GMBH. - SignPath Pharma, Inc.signpathexh106.htm
EX-4.10 - FORM OF SERIES D SUBSCRIPTION AGREEMENT - SignPath Pharma, Inc.signpathexh410.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - SignPath Pharma, Inc.signpathexh311.htm
EX-10.9 - EXCLUSIVE LICENSE AGREEMENT, DATED JUNE 5, 2013, WITH JOHNS HOPKINS UNIVERSITY. - SignPath Pharma, Inc.signpathexh109.htm
EX-10.16 - AMENDMENT NO. 1, DATED JULY 18, 2014, TO THE SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1016.htm
EX-10.17 - AMENDMENT NO. 1, DATED DECEMBER 12, 2014, TO THE EMPLOYMENT AGREEMENT BY AND BETWEEN THE REGISTRANT AND DR. LAWRENCE HELSON. - SignPath Pharma, Inc.signpathexh1017.htm
EX-10.11 - PATENT AND TECHNOLOGY LICENSE AGREEMENT DATED NOVEMBER 25, 2015, BETWEEN THE REGISTRANT AND THE UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER. - SignPath Pharma, Inc.signpathexh1011.htm
EX-10.15 - SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1015.htm
EX-10.12 - PLACEMENT AGENCY AGREEMENT DATED AS OF SEPTEMBER 17, 2014 BY AND BETWEEN SIGNPATH PHARMA INC. AND MEYERS ASSOCIATES L.P. - SignPath Pharma, Inc.signpathexh1012.htm
10-K - SIGHPATH PHARMA 10K 2014-12-31 - SignPath Pharma, Inc.signpath.htm
EX-32.1 - CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - SignPath Pharma, Inc.signpathexh321.htm
Exhibit 10.7
Amendment III
to the Agreement for the Manufacturing of a Liposomal Formulation

 

between

SignPath Pharma, Inc. (“SIGNPATH”)
1375 California RD, Quakertown, PA  18951, USA

and

Polymun Scientific Immunbiologische Forschung GmbH ("POLYMUN'')
Donaustr. 99, 3400 Klostemeuburg, Austria


Pursuant to §11.6 of the Agreement between SIGNPATH and POLYMUN from 6th of September 2007, which stipulates that “Modifications/amendments to or extensions of this Agreement are only valid if in writing and signed for and on behalf of both parties.", SIGNPATH and POLYMUN hereby acknowledge the following Amendment to the Agreement:

Adaptation of Annex 3 with additional production of GMP batches, replacing Part 3 of the scope of work of the Agreement, plus additional stability study:

Part
Description
Time
Price
3
This part includes the manufacture of one additional GMP-compliant batch of liposomes containing approximately 115 g of Ingredient according to specifications for clinical application.  The maximal final volume per batch is 18 liters.  SIGNPATH will supply the GMP-compliant Ingredient and lipids or alternatively cover the costs of Ingredient and lipids procured by POLYMUN.  Sterile filling of the GMP-compliant batch in aliquots of 20 ml to a maximum of several hundred 20 ml glass vials will be performed at POLYMUN.  Primary packaging material (glass vials, stoppers and caps) will be provided by SIGNPATH or alternatively sourced by POLYMUN and reimbursed by SIGNPATH.  For higher numbers of vials, a subcontractor will be organized by POLYMUN in agreement with SIGNPATH and such additional costs paid by SIGNPATH.
10 weeks (not including stability study)
€ 90.000
Additional tasks that might be ordered by SIGNPATH
Set-up for one stability program
--
€10.000
Stability time point per temperature
--
€  3.500
 
 
 
 
 
Payment schedule:

Part 3:
 
•        50% of the costs for Part 3 upon ordering of such additional GMP-compliant batch
 
•        50% of the costs for Part 3 of Annex 2 upon availability of the individual GMP-compliant batch.
 
Additional tasks:
 
       •          100% of the costs for the additional task upon stability study start or on availability of test results per stability time point, respectively

Not included:
 
•        Shipping costs
 
•        Costs for external laboratories (e.g.particulate matter, residual ethanol, endotoxin, sterility)


For SIGNPATH:
For POLYMUN:
  
     
     
/s/ Laurence Helson     Aug. 22, 2012
/s/ Dietmar Katinger     23.08.2012
(Signature/date)
(Signature/date)
  
     
Laurence Helson, MD, CEO
Dr. Dietmar
Katinger, CEO
 
 
 
 
 

SignPath Pharma, Inc. Reports